Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Unresectable Colorectal Cancer 1Triple Negative Breast Neoplasms 1Sezary Syndrome 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Myeloid Malignancies 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × magrolimab × Clear all
NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Gilead Sciences

Phase 2 Terminated
36 enrolled 17 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡